Search

Displaying results 4761 - 4770 of 5261 in total
  1. Drug

    Cinchophen

    go.drugbank.com/drugs/DB13551
    Experimental

    Categories: Preparations With No Effect on Uric Acid Metabolism
  2. Drug

    Aluminium monostearate

    go.drugbank.com/drugs/DB01375
    Experimental

    Also known as dihydroxyaluminium or dihydroxy(stearato)aluminium, it is used to form gels in the packaging of pharmaceuticals and in the preparation of colors for cosmetics.

  3. Drug

    SYNB1353

    go.drugbank.com/drugs/DB17666
    Investigational

    [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria.

  4. Drug

    Unoprostone

    go.drugbank.com/drugs/DB06826
    ApprovedWithdrawn

    Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate. The main indication of Unoprostane is treatment of glucoma.

  5. Drug

    Diphemanil

    go.drugbank.com/drugs/DB13720
    ApprovedVet approvedWithdrawn

  6. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    It is an experimental therapy that is being developed by NeoRx Corporation.

  7. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation

  8. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy

  9. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

  10. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.